Enzon's Debt is Reduced by $116 Million
--Debt converted into an additional 13.5 million shares
Enzon Pharmaceuticals, 03/09/2010
Free full text
Enzon Pharmaceuticals, Inc. announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013. As a result of the sale of the specialty pharmaceutical business on January 29, 2010, the Company was required to offer to repurchase for cash any and all of its convertible notes at face value. This offer expired on March 5, 2010 and no notes were tendered.







